D. E. Shaw & Co. Inc. Has $10.94 Million Holdings in Prestige Consumer Healthcare Inc. (NYSE:PBH)

D. E. Shaw & Co. Inc. decreased its holdings in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) by 14.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 140,104 shares of the company’s stock after selling 23,603 shares during the quarter. D. E. Shaw & Co. Inc. owned about 0.28% of Prestige Consumer Healthcare worth $10,941,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Allspring Global Investments Holdings LLC grew its holdings in Prestige Consumer Healthcare by 3.1% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,624,501 shares of the company’s stock worth $126,274,000 after acquiring an additional 49,331 shares during the period. Geode Capital Management LLC boosted its position in shares of Prestige Consumer Healthcare by 1.7% in the 4th quarter. Geode Capital Management LLC now owns 1,348,745 shares of the company’s stock worth $105,342,000 after purchasing an additional 21,951 shares during the last quarter. Kayne Anderson Rudnick Investment Management LLC acquired a new stake in shares of Prestige Consumer Healthcare during the fourth quarter worth $84,932,000. Invesco Ltd. grew its stake in shares of Prestige Consumer Healthcare by 2.4% during the fourth quarter. Invesco Ltd. now owns 1,060,263 shares of the company’s stock worth $82,796,000 after purchasing an additional 24,392 shares during the period. Finally, Congress Asset Management Co. increased its holdings in Prestige Consumer Healthcare by 5.0% in the fourth quarter. Congress Asset Management Co. now owns 908,742 shares of the company’s stock valued at $70,964,000 after purchasing an additional 43,619 shares during the last quarter. 99.95% of the stock is owned by institutional investors.

Prestige Consumer Healthcare Stock Performance

Shares of PBH stock opened at $85.83 on Thursday. The company has a debt-to-equity ratio of 0.56, a quick ratio of 2.20 and a current ratio of 3.68. Prestige Consumer Healthcare Inc. has a 52 week low of $62.35 and a 52 week high of $90.04. The company’s 50 day moving average price is $83.16 and its two-hundred day moving average price is $81.62. The company has a market capitalization of $4.25 billion, a P/E ratio of 20.10, a price-to-earnings-growth ratio of 2.69 and a beta of 0.44.

Prestige Consumer Healthcare (NYSE:PBH) last issued its quarterly earnings data on Thursday, May 8th. The company reported $1.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.30 by $0.02. The company had revenue of $296.52 million during the quarter, compared to the consensus estimate of $289.36 million. Prestige Consumer Healthcare had a net margin of 19.13% and a return on equity of 12.36%. The firm’s revenue was up 7.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.02 earnings per share. On average, analysts expect that Prestige Consumer Healthcare Inc. will post 4.5 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. DA Davidson raised their target price on Prestige Consumer Healthcare from $95.00 to $104.00 and gave the stock a “buy” rating in a report on Friday, February 7th. Oppenheimer lifted their price objective on shares of Prestige Consumer Healthcare from $87.00 to $93.00 and gave the stock an “outperform” rating in a research note on Thursday, February 13th. StockNews.com downgraded shares of Prestige Consumer Healthcare from a “buy” rating to a “hold” rating in a research note on Friday, May 9th. Royal Bank of Canada upgraded shares of Prestige Consumer Healthcare to a “hold” rating in a report on Thursday, May 8th. Finally, Canaccord Genuity Group boosted their price target on shares of Prestige Consumer Healthcare from $93.00 to $100.00 and gave the company a “buy” rating in a report on Friday, February 7th. Four investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $93.33.

Insider Buying and Selling

In other Prestige Consumer Healthcare news, SVP Mary Beth Fritz sold 1,678 shares of the company’s stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $90.00, for a total transaction of $151,020.00. Following the completion of the transaction, the senior vice president now owns 17,157 shares of the company’s stock, valued at $1,544,130. This represents a 8.91% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 1.60% of the stock is owned by corporate insiders.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.